ArticleThe Journal of experimental medicine2018
Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation.
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Lymphocyte-mediated immune responses to Leishmania infection.Nature reviews. Immunology · 2026Review
- Stem-like CD4 T cells in tumors: an emerging framework for antitumor immunity.Frontiers in immunology · 2026Review
- Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy.Cellular & molecular immunology · 2026Review
- Progenitor exhausted PD-1Nature cardiovascular research · 2025Article
- Beyond T-cell subsets: stemness and adaptation redefining immunity and immunotherapy.Cellular & molecular immunology · 2025Review
- Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.Cancer research · 2024Article
- Article
- The redox sensor KEAP1 facilitates adaptation of T cells to chronic antigen stimulation by preventing hyperactivation.Science immunology · 2024Article
- Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends.Experimental & molecular medicine · 2024Review
- Inflammatory Gene Panel Guiding the Study of Genetics in Inflammatory Bowel Disease.Molecular diagnosis & therapy · 2024Review
- Stem-like T cells are associated with the pathogenesis of ulcerative colitis in humans.Nature immunology · 2024Article
- Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- Durable CD4Trends in immunology · 2024Review
- The multifaceted roles of TCF1 in innate and adaptive lymphocytes.Advances in immunology · 2024Review
- Review
- Defining a TCF1-expressing progenitor allogeneic CD8Nature communications · 2023Article
- Intrinsic STAT4 Expression Controls Effector CD4 T Cell Migration and Th17 Pathogenicity.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- A Set of Dysregulated Target Genes to Reduce Neuroinflammation at Molecular Level.International journal of molecular sciences · 2022Article
- Sweet Immune Checkpoint Targets to Enhance T Cell Therapy.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dysregulated CD4 T cell responses are causally linked to autoimmune and chronic inflammatory disorders, yet the cellular attributes responsible for maintaining the disease remain poorly understood. Herein, we identify a discrete population of effector CD4 T cells that is able to both sustain and confer intestinal inflammation. This subset of pathogenic CD4 T cells possesses a unique gene signature consistent with self-renewing T cells and hematopoietic progenitor cells, exhibits enhanced survival, and continually seeds the terminally differentiated IFNγ-producing cells in the inflamed intestine. Mechanistically, this population selectively expresses the glycosyltransferase ST6Gal-I, which is required for optimal expression of the stemness-associated molecule TCF1 by effector CD4 T cells. Our findings indicate that the chronicity of T cell-mediated inflammation is perpetuated by specific effector CD4 T cells with stem-like properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.